Genentech, Inc.
M.D. clinically trained ophthalmologist. Expertise includes Ph.D. in immunology; 14 years in clinical ophthalmology practice and academic research at Charles University, Department of Ophthalmology & Visual Sciences, Washington University, Schepens Eye Research Institute & Children's Hospital Boston, Harvard University; 15 years in biopharmaceutical Ophthalmology and Immuno-Oncology drug development at GlaxoSmithKline and Genentech. Managed teams and individual contributors, external and internal stakeholder relationships, and served as the site head, Everwise mentor and coach to colleagues, fellows and interns. Led projects from discovery research, target selection through antibody candidate development to Early Stage & Late Stage Clinical Trials and Investigator Initiated Studies. Served as the Clinical Science Lead on numerous health authority interactions supporting IND, BLA, sBLA, PAS filings, ODD and PIP applications. Achieved 3 research patents, 3 successful regulatory Priority Reviews, 2 successful Breakthrough Designations, and 5 Regulatory Approvals. Served as the Lead Clinician on a number of Phase 2 and Phase 3 trials with darapladib, anti-beta amyloid antibody, ranibizumab and faricimab in retina diseases, served as the clinical lead on home-monitoring and predictive machine learning algorithm development in retina diseases, and novel disease indication search for CD20, IL6R and BTK targeting therapies. Presented and published over 130 presentations & posters at congresses and peer-reviewed manuscripts. Flexible and constantly learning new skills.
